Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the...
Turalio (pexidartinib) for the Treatment of Tenosynovial Giant Cell Tumour
Turalio™ (pexidartinib) is the first drug approved for the treatment of tenosynovial giant cell tumour (TGCT) in adult patients.
Baqsimi (glucagon) for the Treatment of Severe Hypoglycaemia
Baqsimi™ (glucagon) is the first nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycaemia in diabetes patients aged four years and above.
Jeuveau (prabotulinumtoxinA-xvfs) for the Treatment of Frown Lines
Jeuveau™ (prabotulinumtoxinA-xvfs) is a neurotoxin indicated for temporary improvement of moderate to severe glabellar lines, called frown lines.
Vyleesi (bremelanotide) for the Treatment of Hypoactive Sexual Desire Disorder
Vyleesi™ (bremelanotide) is a peptide drug indicated for treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
Humira for the Treatment of Hidradenitis Suppurativa
Humira (adalimumab) is a monoclonal antibody indicated for the treatment of more than ten indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), and uveitis.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Rozlytrek (entrectinib) for the Treatment of Solid Cancerous Tumours
Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced solid tumours in adult and paediatric patients.
Zynteglo for the Treatment of Transfusion-Dependent Beta-thalassemia
Zynteglo™ is a gene therapy indicated for the treatment of transfusion-dependent beta (β)-thalassemia (TDT) in patients aged 12 years and older.
Piqray (alpelisib) for the Treatment of Advanced Breast Cancer
Piqray® (alpelisib) is a kinase inhibitor indicated for the treatment of hormone receptor (HR) positive or HER2-negative advanced breast cancer with PIK3CA mutation in men and post-menopausal women.